Handelsbanken Fonder’s Coherus Oncology CHRS Stock Holding History

Handelsbanken Fonder’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,000	Closed	-$178K	–	1583
2023 Q1	$178K	Hold	26,000	–	–	﹤0.01%	1472
2022 Q4	$206K	Buy	26,000 +7,200	+38%	+$55.4K	﹤0.01%	1426
2022 Q3	$181K	Hold	18,800	–	–	﹤0.01%	1453
2022 Q2	$136K	Hold	18,800	–	–	﹤0.01%	1551
2022 Q1	$243K	Hold	18,800	–	–	﹤0.01%	1588
2021 Q4	$300K	Hold	18,800	–	–	﹤0.01%	1614
2021 Q3	$302K	Hold	18,800	–	–	﹤0.01%	1588
2021 Q2	$260K	Buy	18,800 +8,600	+84%	+$122K	﹤0.01%	1665
2021 Q1	$149K	Hold	10,200	–	–	﹤0.01%	1552
2020 Q4	$177K	Hold	10,200	–	–	﹤0.01%	1528
2020 Q3	$187K	Hold	10,200	–	–	﹤0.01%	1397
2020 Q2	$182K	Buy	+10,200	New	+$173K	﹤0.01%	1391
2017 Q4	–	Sell	-70,000	Closed	-$934K	–	195
2017 Q3	$934K	Buy	70,000 +15,000	+27%	+$198K	0.02%	167
2017 Q2	$789K	Buy	55,000 +10,000	+22%	+$192K	0.02%	161
2017 Q1	$952K	Hold	45,000	–	–	0.03%	159
2016 Q4	$1.27M	Hold	45,000	–	–	0.04%	141
2016 Q3	$1.21M	Hold	45,000	–	–	0.04%	143
2016 Q2	$760K	Sell	45,000 -10,000	-18%	-$188K	0.03%	136
2016 Q1	$1.17M	Sell	55,000 -100,000	-65%	-$1.64M	0.05%	124
2015 Q4	$3.56M	Buy	+155,000	New	+$3.99M	0.07%	237

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Handelsbanken Fonder's CHRS Position: Q2 2023 in Review

Handelsbanken Fonder sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 26,000 shares — an estimated $178K sold.

Handelsbanken Fonder first reported a position in CHRS in Q4 2015 and held it in 20 quarters. The position peaked at $3.56M in Q4 2015. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Handelsbanken Fonder reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
Handelsbanken Fonder sold 26,000 Coherus Oncology shares in Q2 2023, an estimated $178K.
Handelsbanken Fonder first reported a position in Coherus Oncology in Q4 2015 and held it in 20 quarters.
Handelsbanken Fonder's Coherus Oncology position peaked at $3.56M in Q4 2015.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Handelsbanken Fonder's 13F filing for Q2 2023, filed 2 Aug 2023.